4. What is the downside of DTC genetic testing?“If you are unaware of certain risks in your family, youmay scan the results, quickly dismissing some whilebeing overly concerned about others. People mightsee that they have a high lifetime risk of a certaincancer and feel alarmed, whereas if they saw a geneticcounselor they would know that there are ways toreduce the risk and potentially never get cancer,” Dr.Hall said.

Forman cautioned about false positive results (resultsthat show something is present when it really is not).Some common genetic variants are also misclassifiedas being associated with increased risk. It turns outthat DTC testing may involve “spot checking” yourresults, not the comprehensive analysis done duringroutine clinical diagnostic testing, she said. Positiveresults are typically not confirmed with a “doublecheck” test, which is recommended in clinical genetictesting labs.

5. What does Fox Chase offer that does not come withDTC testing for cancer risk?“There are advantages to coming to Fox Chase ratherthan doing at-home genetic testing,” Hall said. “Forpatients who have a genetic risk, we can discussscreening, prevention, and treatment options thatmay benefit them. We can guide patients who needtreatment to new therapeutic targets that may lead toclinical trials. We help patients’ family members getscreened, if appropriate.

Continued on page 2

Nowadays, looking into “what makes you, you” takesas little as six weeks. At-home DNA tests can providevaluable insight into your risk for certain diseases,including some cancers, but these tests aren’tfoolproof, and the results may not tell the full story ofhow your genes could affect your health.

1. What is at-home, or direct-to-consumer (DTC),genetic testing?There are a number of DTC test kits you can orderwithout a doctor’s prescription that offer personalizedgenetic analyses ranging from ancestry to healthrisks. The health tests may tell you what your risk fora certain disease is, like cancer or Alzheimer’s. It isimportant to remember that DTC tests detect geneticmarkers that may increase disease risk, but being atrisk for a disease does not mean you will ever get thedisease.

2. Are DTC tests a good place to start for patientsconcerned about cancer?“Conducting DTC tests to learn more about yourancestry can provide fun, interesting information,”Dr. Hall said. “My concern is with predictive tests formedical issues. It is optimal for patients receivingmedical information to have genetic counseling, or atleast have a physician oversee the process.”

Forman agreed. “How confident can an individual be iftest results don’t show any risks? Several other factors,such as lifestyle choices and family history, can alsoaffect disease risk.”

3. Are there benefits to DTC genetic testing?DTC tests can raise public awareness about geneticinformation. Some tests can be ordered in partnershipwith a doctor and may provide a way for people toget screened even if they live far away from a testingcenter, cannot afford testing, or get denied coverage forscreening because they don’t have a family history ofdisease, according to Forman.

IN THIS ISSUERESEARCH NEWS • page 3HIGH-RISK CLINICS PROVIDE 27 YEARS OF OUTSTANDING SERVICE • page 4MAN 2 MAN • page 6

Preventionmatters| A FOX CHASE CANCER CENTER RISK ASSESSMENT PROGRAM PUBLICATION | FALL/WINTER 2018 |

Things You Should Know About At-Home Genetic Tests for CancerBy Michael J. Hall, MD, MS, Interim Chair, Department of Clinical Genetics, and Andrea Forman, MS, LCGC, Senior Genetic Counselor

20448.indd 1 9/19/18 5:59 PM

2 | FALL/WINTER 2018 | Preventionmatters

We offer family planning for anyone concerned aboutpassing on certain genetic risks to their children.Social services are also available for patients who feeloverwhelmed or distressed.”

6. What can a genetic counselor do for potential cancerpatients?“We want people to talk to a genetic counselor beforeand after they get screened, so they know what they aregetting into, what the results mean, and what to do next,”Hall said.

Forman added, “One of the big benefits is havingsomebody be your advocate to make sure you are makingdecisions for yourself and your family based on goodinformation. We are also good at helping with logistics;insurance coverage, which lab to use, and makingsure the test they take will provide the right amount ofinformation.”

This spring, Fox Chase Cancer Center opened adedicated outpatient cancer facility on the campus ofSuburban Community Hospital in East Norriton, PA.The Fox Chase East Norriton campus offers radiationoncology and medical oncology for a variety of cancertypes, as well as surgical consultations for breast,gynecologic and urologic cancer patients. Surgerieswill be performed at the Fox Chase main campus inPhiladelphia. Nurse navigators are available to makesure patients are seen by the appropriate cancercare specialists.

Clinical genetics services will be provided by CatieNeumann, MS, LCGC. Clinical genetics services arecurrently available in three different locations: FoxChase Cancer Center’s main campus in Philadelphia,Fox Chase radiation therapy center in Buckingham,Bucks County and now in East Norriton, MontgomeryCounty. In the near future, research studies andclinical trials are expected to be available at FoxChase East Norriton.

IN THE NEWS: Fox Chase East Norriton

Genetic counseling team. Left to right: Michelle Savage, CatieNeumann, Sue Montgomery, Andrea Forman and Kim Rainey

7. What is all the buzz about DTC testing for BRCA1/2 breast cancer gene mutations?This DTC test addresses only three specific BRCA1/2 gene mutations out of more than 1,000 known BRCA mutations.It is important to understand that these three mutations are the most common mutations in people of AshkenaziJewish descent, but are not the most common BRCA mutations in the general population. “It scares me that awoman will take the DTC test, find out she doesn’t have one of these three mutations, and the negative results willfalsely reassure her,” said Forman.

“The positive side to this DTC test is that it can raise awareness about BRCA1/2 gene mutations for women andmen,” Hall said. “Many people do not realize that BRCA genes are predictive of prostate and other cancers in men.In fact, the national guidelines recommend BRCA testing for metastatic prostate cancer. This expertise differentiatesbetween getting counseling and screening at Fox Chase instead of using a DTC kit.”

If you remember one thing, remember this: Having a risk for cancer doesn’t mean you will ever get it. If you haveconcerns about cancer risk, let genetic counselors help.

Things You Should Know About At-Home Genetic Tests for Cancer continued from front cover

I recently moved from SouthernCalifornia, but I am no stranger tothe Philadelphia area. I grew up inBucks County, Pennsylvania andreceived my Bachelor of Science inPsychology from Lafayette Collegein Easton, Pennsylvania. Afterearning my undergraduate degree,I worked as a research assistant atTufts Medical Center studying thegenetic and environmental factors ofmacular degeneration and later asa research assistant at University ofCalifornia Los Angeles for a clinicaltrial studying immunotherapy inpatients with lung cancer. I went

Catherine Neumann,MS, LCGCLicensed CertifiedGenetic Counselor

on to complete my Masters in Genetic Counseling at BostonUniversity. Prior to starting at Fox Chase, I worked as a geneticcounselor in Metabolic Genetics at Children’s Hospital of OrangeCounty and in Cancer Genetics at St. Joseph Hospital in Orange,California. I am thrilled to return to the Philadelphia area and tobe working with the RAP team.

WELCOME ABOARD

20448.indd 2 9/24/18 1:07 PM

whether chemotherapy is beneficial for women with a mid-rangerecurrence score of 11 to 25.The study measured invasive disease-free survival, defined as nothaving an invasive disease recurrence,a second diagnosis of breast cancer,or death. After 9 years of follow-up,the rates of invasive disease-freesurvival were 83.3% for hormonetherapy alone and 84.3% for hormonetherapy and chemotherapy, andfor overall survival, the rates were93.9% and 93.8%, respectively. Researchers found thatchemotherapy provided no additional benefit over hormonetreatments alone in women who were above age 50. Inwomen who were 50 and below, chemotherapy benefit wasseen with regards to invasive disease–free survival, in thosewith an Oncotype DX score between 16 and 25.

“These results are indeed practice-changing and willsave thousands of women from getting unnecessarychemotherapy,” said Elias Obeid, MD, MPH director of theBreast, Ovarian and Prostate Cancer Risk AssessmentProgram at Fox Chase Cancer Center.

“With evidence-based recommendation, we can now de-escalate treatment, avoid chemotherapy, treat only withhormonal therapy, and still have a great survivorship ratewith early-stage breast cancer”, Dr. Obeid said.

Read full article at: https://www.nejm.org/doi/10.1056/NEJMoa1804710

RESEARCH NEWS

According to a new federally funded study published inthe New England Journal of Medicine, many patients whoare diagnosed with early-stage (I or II) hormone-receptor-positive breast cancer, will not need chemotherapy aftersurgery. This depends on a specific score on the OncotypeDX genomic test.

Oncotype DX is a test that can help predict if certain earlystage breast cancers will benefit from chemotherapy aftersurgery. The test looks at 21 genes in cancer cells frombreast tumor biopsy samples to get a “recurrence score”between 0 and 100. The higher the score, the greater thechance the cancer will come back and, thus might benefitfrom chemotherapy. Not all patients would benefit fromchemotherapy. Previous studies have found that womenwith scores above 30 would benefit from chemotherapyand those with scores less than 18 would not. Women withscores 18-31 are considered to have an intermediate riskscore, and the benefit from chemotherapy was less clear.More recent updates show that when the score is less than11, there is a definite lack of benefit from chemotherapy.Overall, these patients did very well with hormonal therapywithout chemotherapy.

In the TAILORx (Trial Assigning Individualized Optionsfor Treatment) trial, 10,273 women participated. Thistrial included women with early stage hormone receptorpositive (ER and/or PR) and HER2 negative breast cancer. The trial looked at 6,711 women with a newly defined mid-range score. The new definition was a score of 11 to 25.The participants were randomly assigned to receive eitherchemotherapy before hormonal therapy or hormonaltherapy alone. The goal of the study was to find out

Many Breast Cancer Patients Can Safely Skip Chemo

We would like to invite you toparticipate in a new researchopportunity for patients with Lynchsyndrome that is available at FoxChase Cancer Center througha collaboration between theGastrointestinal Risk AssessmentProgram (GI-RAP) led by Dr.Michael Hall, the Department ofGastroenterology (Dr. Minh Nguyen),and the research laboratory of Dr.Margie Clapper.

This study is looking at new waysto lower the risk of developingcolorectal cancer by taking aspirin,an oral medication commonly usedfor treatment and prevention, and

atorvastatin (known commerciallyas Lipitor), a medication that treatshigh cholesterol. It is our hope thatthe results of this research will behelpful in developing better ways toprevent colorectal cancer in patientswith Lynch syndrome.

For this study, we are looking forpatients with Lynch syndromewho currently have their screeningcolonoscopies performed atFox Chase Cancer Center orwho would be willing to do theirusual screening colonoscopy atFox Chase Cancer Center one timeand take a preventive medication(s)for 6 weeks.

Michael Hall, MD and MargieClapper, PhD have received anaward for this translational clinicaltrial proposal, entitled: “Preventionof Colorectal Adenomas in Patientswith Lynch Syndrome usingAtorvastatin and Aspirin:An Exploratory Biomarker Trial.”

For more information please callYana Chertock at 215-214-3216

CLINICAL TRIAL OPPORTUNITY FOR LYNCH SYNDROME PATIENTS

OCTOBER IS BREAST CANCER AWARENESS MONTH

Dr. Elias Obeid, MD, MPH

20448.indd 3 9/19/18 5:59 PM

HIGH-RISK CLINICS PROVIDE 27 YEARS OF OUTSTANDING SERVICEOur first- high risk clinic at Fox Chase Cancer Centeropened its doors in 1991 for women with increased riskfor breast and ovarian cancers due to family history whowere looking for close medical follow-up. Today theDepartment of Clinical Genetics has 3 high -risk clinicsthat work with our Risk Assessment Program (RAP)which provides genetic counseling and testing and accessto research participation.

Our team of physicians and nurses helps individuals andfamilies evaluate their risk for different types of cancerand to develop a healthcare plan for screening, cancerprevention and early detection.

HIGH-RISK BREAST AND OVARIAN CANCER CLINICSPractitioners: Mary Daly, MD, PhD; Elias Obeid, MD,MPH; Kristen Whitaker, MD; Kathryn Tumelty, CRNP,FNP-C, AOCNP; Sharon Schwartz, MSN, CRNP; SusanMontgomery, BSN, RN, GCN, OCN

High Risk Breast and Ovarian Clinics are open to womenwith:• A family history of breast and/or ovarian cancer• A positive genetic test result [this means a

pathogenic variant or mutation was found on genetictesting]

• A breast biopsy finding that is not cancer, butincreases risk for breast cancer in the future

Our clinics provide:• Clinical breast examinations (annually or semi-

annually)• Education for patients to perform breast self-exams• Screening recommendations (MRI, mammography)• Cancer prevention discussion (chemoprevention, e.g.

Tamoxifen)• For women with a gene mutation, we review the

options for risk-reducing surgeries• Opportunity to participate in clinical trials and

research studies looking at new approaches for earlydetection and risk reduction

HIGH-RISK PROSTATE CLINICPractitioners: Elias Obeid, MD, MPH and David Chen, MD,FACS; Susan Montgomery, BSN, RN, GCN, OCN

Our Prostate Risk Assessment Program (PRAP) is aresearch and clinical program open to men who are athigh risk of prostate cancer.

PRAP program is open to:• Men 35 to 69 years of age• With at least one first-degree relative (such as

brother or father) with a diagnosis of prostate canceror

• With at least two second-degree relatives withprostate cancer (such as two uncles) on the sameside of the family (either paternal or maternal) or

• Who have tested positive for a gene mutation or• Who are African-American regardless of family

cancer history

PRAP program provides:• Opportunity to be part of a research/clinical program

focused on early detection and prevention of prostatecancer

• Yearly clinical exam and a digital rectal exam (DRE)• Prostate-Specific Antigen (PSA) blood test• Evaluation of cancer risk based on family history• Opportunity to be part of clinical trials and additional

research studies (when available)

HIGH-RISK GASTROINTESTINAL CLINICPractitioners: Michael Hall, MD, MS; Kathryn Tumelty,CRNP, FNP-C, AOCNP

High-Risk Gastrointestinal (GI RAP) clinic is open to:• Individuals with personal or family history of

gastrointestinal cancers [Colorectal Cancer; Esophageal Cancer; Liver, Gall Bladder & BileDuct Cancer; Neuroendocrine Tumors; PancreaticCancer; Stomach Cancer]

• Individuals with hereditary cancer syndromes[Lynch syndrome, Familial Adenomatous Polyposis(FAP), Attenuated FAP, MutYH-associated polyposis(MAP), Peutz-Jeghers syndrome, Juvenile Polyposis,Cowden syndrome, Hereditary Diffuse Gastric Cancer,Familial Pancreatic Cancer, Serrated polyposissyndrome (SPS), and Li-Fraumeni syndrome]

GI RAP clinic provides:• Yearly clinic appointments for patients who test

positive for a gene mutation. This clinic helps thesepatients with expert medical care and screening teststo detect cancer at an earlier, more treatable stage.

Continued on page 5

4 | FALL/WINTER 2018 | Preventionmatters

Dr. Mary Daly with a patient in high risk clinic

20448.indd 4 9/24/18 10:13 AM

• Pancreatic cancer accounts for about 3% of all cancers inthe US and about 7% of all cancer deaths.

• In 2018, about 55,440 Americans will be diagnosedwith pancreatic cancer, according to American CancerSociety estimate. The number of new cases and deaths isprojected to double by 2030.

Are there screening tests for pancreaticcancer?Pancreatic cancer is hard to detect early. The pancreas isdeep inside the body, so early tumors can’t be seen or felt byhealth care providers during routine physical exams. Peopleusually have no symptoms until the cancer has already spreadto other organs.

At this time, no major professional groups recommendroutine screening for pancreatic cancer in people who areat average risk. This is because no screening test has beenshown to lower the risk of dying from this cancer.

Although there are no screening tests currently available toscreen the general population, investigators at Johns Hopkinsare using current technologies like endoscopic ultrasoundto screen for pancreatic cancer. It is hoped that these testsmay prove effective when used in increased risk populationssuch as individuals with a strong family history of pancreaticcancer, or with a specific genetic syndrome.

CAPS5 studyThe Cancer of the Pancreas Screening Study 5 (CAPS5) wasdeveloped to evaluate the effectiveness of early detectionscreening with endoscopic ultrasound in individuals at highrisk for pancreatic cancer. This study is run by investigatorsfrom John Hopkins University and is open in seven differentlocations including hospitals in Pennsylvania and New York.

CAPS5 clinical trial is offered for individuals who have a highrisk of developing pancreatic cancer based on their familyhistory, genetic predispositions, and certain diagnoses.

All participants must be at least 18 years old and meet one ofthe criteria below:

• Hereditary PancreatitisConfirmed gene mutations that predispose to chronicpancreatitis (such as PRSS1, PRSS2, CTRC) and age 50 yearsor older, or twenty-years since first attack of pancreatitis,whichever age is younger

• Peutz-Jeghers SyndromeAt least 30 years old, and have at least 2 of 3 criteriafor Peutz-Jeghers syndrome (characteristic intestinalhamartomatous polyps, mucocutaneous melanin deposition,or family history of Peutz-Jeghers syndrome), or knownSTK11 gene mutation carrier

• Strong family history of pancreas cancer on one side of thefamily tree

≥ 55 years old, or 10 years younger than the age of youngestrelative with pancreatic cancer, and come from a family with2 or more members with a history of pancreatic cancer,and have a first-degree relationship with at least one of therelatives with pancreatic cancer.

• Germline mutation carrier

≥ 50 years old, or 10 years younger than the age of theyoungest relative with pancreatic cancer, and the patient is acarrier of a confirmed mutation in CDKN2A, BRCA2, BRCA1,ATM, PALB2 or Lynch syndrome genes: MLH1, MSH2, PMS1,MSH6, EPCAM; and there is 1 or more pancreatic cancerdiagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.

For more information:https://clinicaltrials.gov/ct2/show/NCT02000089

November is Pancreatic Cancer Awareness Month

HIGH-RISK CLINICS... continued from page 4

In addition, we can help individuals with rare hereditarycancer syndromes with a broad spectrum of services,such as cancer risk assessment for patients and theirfamily members, appropriate screening, and access toclinical trials and research opportunities. Rare hereditarysyndromes include but are not limited to:

• Hereditary Renal Cancers (Birt Hogg Dube, HLRCC,BAP1, others)

• Hereditary Endocrine and NeuroendocrineCancers (Thyroid, Adrenal, Paraganglioma,Pheochromocytoma)

• Hereditary Endometrial and Uterine Cancers• Hereditary Sarcomas• Hereditary Melanoma

FALL/WINTER 2018 | Preventionmatters | 5

To make an appointment, please call 215-728-4765 or 215-728-2683

20448.indd 5 9/24/18 10:13 AM

Risk Factor is defined as something that affects yourchance of getting a disease. Cancer can have manydifferent risk factors. Some risk factors can be changedand others cannot. For example a person cannot changetheir age, race or family history.

Having a risk factor does not mean a person will get cancer.Some people with multiple risk factors will get cancer andothers with no risk factors will still get cancer.

Risk Factors that might affect a man’s risk for gettingprostate cancer are:

• AgeProstate cancer is rare in younger men, but chances ofgetting prostate cancer rise as a man gets older. About6 in 10 cases of prostate cancer are found in men olderthan 65.

• Race/EthnicityAfrican American men are more likely to die of prostatecancer than Caucasian men. Prostate cancer occursless often in Asian and Hispanic/Latino men than innon-hispanic white men. The reasons for this are notyet clear.

• Family HistoryProstate cancer seems to run in some families, thismay mean there is an inherited or genetic risk factor.

Men having a father or brother with prostate cancercan double a man’s risk of developing this cancer. Therisk is even higher for men with multiple (more thanone) family members with prostate cancer especially ifthey were diagnosed at a young age.

• Inherited mutationsMutations in the BRCA1 and BRCA2 genes may raisea man’s risk of developing prostate cancer. There aremore newly discovered genes, for example the HOXB13gene, that research suggests may also raise a man’srisk to develop the disease.

Other potential risk factors still being studied are:• Diet• Obesity• Smoking• Chemical exposure• Inflammation of the prostate• Sexually transmitted infections• Vasectomy• Geography (where you come from)

For more information:www.cancer.org/cancer/prostate-cancer/early-detection/risk-factors-for-prostate-cancer.html

PROSTATE CANCER RISK FACTORS

Dr. Whitaker is happy to be backin Philadelphia and working atFox Chase. She received herundergraduate degree at theUniversity of Pennsylvania andearned her medical degree fromDrexel University College ofMedicine. She went on to completeher internal medicine residency atthe George Washington UniversityHospital and hematology/oncologyfellowship at the University ofChicago with a focus on breastcancer and clinical genetics.

I chose to work at Fox Chase whenwe relocated to the Philadelphiaarea in 2007 to continue my careerin oncology at an academic cancercenter. I had started my careerat Duke University and wanted tocontinue to practice at a center thatwas dedicated to providing quality,up to the minute care.

I spent over 10 years in the breastmedical oncology department atFox Chase working with womenwho were diagnosed with breastcancer. It is such a rewardingcareer to work with these incredibly

MAN 2 MAN

Kristen Whitaker, MDAssistant Professor,Breast Cancer Risk

Kathryn Tumelty,CRNP, FNP-C, AOCNPNurse Practitioner

As a member of the clinical genetics team, Dr. Whitaker looksforward to counseling patients on interventions to help lowertheir chance of developing cancer. She also looks forward totreating breast cancer patients and guiding them through theirbreast cancer journey.

strong women. In 2018 I transitioned from medical oncologyto the Department of Clinical Genetics and Risk Assessment.I now get to help patients in a high risk clinic before they arediagnosed with cancer with hopes of preventing it and guidethose at an increased risk.

WELCOME ABOARD

6 | FALL/WINTER 2018 | Preventionmatters

20448.indd 6 9/19/18 5:59 PM

What’s in Winter Squash?

True American natives, winter squash havehard skins unlike the soft-skinned summersquash. They also come in a wonderful varietyof colors, textures and flavors. The mostcommon varieties you’ll see in supermarketsare acorn, butternut, spaghetti and hubbard.

Winter squash are excellent sources ofvitamin A, as well as good sources of vitaminC and dietary fiber. They are also a good wayto get potassium.Winter squash, including pumpkins, are richin carotenoids, including:• beta-carotene and alpha-carotene: these

carotenoids can act as antioxidants. Also,

our bodies convert these to vitamin A, anutrient important for immune functionand maintaining healthy cells amongother roles.

• lutein and zeaxanthin: these yellowpigmented carotenoids help protect eyehealth by filtering high-energy ultravioletrays that can damage our eyes’ lens andretina. They act as antioxidants here andpossibly elsewhere in our bodies.

Reprinted with permission from the AICRwww.aicr.org/healthyrecipes/

HEALTHY RECIPE

FALL/WINTER 2018 | Preventionmatters | 7

FOODS THAT FIGHT CANCER- WINTER SQUASH

Roasted Butternut Squash with Sautéed Shiitake Mushrooms and Fresh Sage

Butternut squash is just coming into season and this simple sauté is one of many ways it can be enjoyed. Roasted and thensautéed with shiitake mushrooms, this unexpected combination is flavorful and full of cancer-fighting carotenoids. Fresh sage brings out the sweetness in the squash.

Directions:Preheat oven to 350 degrees F.In medium size bowl, toss squash with 1 tablespoon olive oil.Arrange butternut squash on baking pan. Roast until fork tender, about 25-30 minutes. Set aside.In large skillet, heat remaining oil over medium-high heat. Add mushrooms, garlic and pinch of salt and sauté 4 minutes.Add sage leaves and continue sautéing 2 minutes. Mix in squash. Continue to sauté another minute. Season to taste withpepper and serve warm garnished with cheese.

Makes 4 ServingsPer serving: 121 calories, 7 g total fat (1 g saturated fat),14 g carbohydrate, 2.5 g protein, 2.5 g dietary fiber, 25 mg sodium.

• 3 cups cubed butternut squash, 1/2-inch (1 lb.)• 2 Tbsp. extra virgin olive oil, divided• 4 oz. package fresh shiitake mushrooms, sliced• 2 cloves garlic, minced

• Salt• 4 fresh sage leaves, coarsely chopped• Freshly ground black pepper• 1 Tbsp. freshly grated Parmesan cheese

Ingredients:

We welcome new clinical genetics intake coordinatorsDebbie Connelly-Sheppard and Maggie O’Connell tothe RAP team!

27Fox Chase Cancer Center

Risk Assessment Program

Celebrating 27 Years

1991-2018

FOODS THAT FIGHT CANCER- WINTER SQUASH

20448.indd 7 9/19/18 5:59 PM

Preventionmatters

Risk Assessment Program

333 Cottman Avenue

Philadelphia, PA 19111-2497

Non-Profi tOrganizationU.S. Postage

PAIDPhiladelphia, PAPermit No. 3187

The Department of Clinical Genetics offers one of themost comprehensive risk assessment programs in thePhiladelphia region. It encompasses all of Fox ChaseCancer Center’s clinical services for people at risk forcancer, as well as innovative research in the areas ofcancer prevention and genetics.

Mary Daly, MD, PhDDirectorRisk Assessment Program

Kristen Whitaker, MDAssistant ProfessorBreast Cancer Risk

Michael Hall, MD, MSInterim ChairDepartment of Clinical Genetics

Elias Obeid, MD, MPHAssistant ProfessorDirectorBreast, Ovary, and ProstateCancer Risk

CONTACT THE RISK ASSESSMENT PROGRAM:1-877-627-9684 | foxchase.org/rap | rapinfo@fccc.edu

Editors: Yana Chertock, Lisa Bealin, Meredith Patrick and Joann Sicilia Designed by 4545 Creative

For more details about events visit www.foxchase.org/events

SATURDAY, OCTOBER 6, 2018Philadelphia International Dragon Boat Festival 20188:00amBoathouse Row, Kelly Drive, Schuykill River, Philadelphia, PA

SUNDAY, OCTOBER 21, 2018Paws for the Cause 20189:00am to 12:00pmFox Chase Cancer Center Reimann Building Parking Area

SATURDAY, NOVEMBER 17, 2018Pink, Purple Strength and Unity ConferenceThis is a FREE EVENT for breast cancer patients, survivors, and families10:00 am to 2:00pm Loews Philadelphia Hotel 1200 Market Street33rd Floor Philadelphia, PA https://bit.ly/2LHQqT8

MA R K YO U R C A L E N DA R

20448.indd 8 9/19/18 5:59 PM